Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer Metastatic: early-phase trial registry
10 of 18 indexed Prostate Cancer Metastatic trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 10 currently recruiting · #953 of 28,707 conditions by registered trial count
Prostate Cancer Metastatic: 18 US clinical trials tracked, 10 recruiting.
Prostate Cancer Metastatic is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Orion Corporation, Orion Pharma, running 1 of these trials.
Enrollment posture brief
Registry condition prostate-cancer-metastatic
OPEN 10 | RECR 56% | LATE 2 | EARLY 9 | RANK #953 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Lymphoblastic Leukemia, Pediatric (56% recruiting · 9 trials)
Prostate Cancer Metastatic lists 10 open slots (56% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer Metastatic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer Metastatic is recruiting above its size-band peers.
10 of 18 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer Metastatic trials is spread across many organizations.
Orion Corporation, Orion Pharma accounts for 1 of 18 trials (5.6%). 18 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer Metastatic enrolment sits around 80 participants.
Median target enrolment is 80 among the 18 trials that report a genuine target (sentinel values excluded). 10 of those (55.6%) plan for fewer than 100 participants.
-
Prostate Cancer Metastatic research is mostly interventional.
14 interventional and 4 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Merck Sharp & Dohme
NCT06136624
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
Martha Mims
NCT03833921
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Duke University
NCT06141993
Geriatric Assessment and Technology Evaluation in Prostate Cancer
University of Chicago
NCT06215508
Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
University of California, San Francisco
NCT06171139
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
Dana-Farber Cancer Institute
NCT05327465
Castrate Resistant Prostate Cancer Enhertu Therapy
Washington D.C. Veterans Affairs Medical Center
NCT06610825
FTT PET/CT in Metastatic Prostate Cancer
Abramson Cancer Center at Penn Medicine
NCT05242744
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Ebrahim S Delpassand
NCT06972628
Exercise in Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06165302
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
Orion Corporation, Orion Pharma
NCT03436485
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Novartis Pharmaceuticals
NCT05067140
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
Alliance Foundation Trials
NCT04335682
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT04030338
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
University of Michigan Rogel Cancer Center
NCT04848337
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Mark Stein
NCT03951831
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
NCT02913196
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Bavarian Nordic
NCT01322490
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer Metastatic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer Metastatic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer Metastatic page
18 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Prostate Cancer Metastatic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Orion Corporation, Orion Pharma sponsors the most Prostate Cancer Metastatic trials on record, review their full trial history before evaluating a specific study. See Orion Corporation, Orion Pharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer Metastatic condition card totals 18 registered trials; most-linked intervention Abiraterone acetate; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.